This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer RNA-editing platform technology.
… Strategic collaborations like this can help to drive the advancement of an early-stage technology, like Axiomer, … expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner … and nervous system. Through the course of work to date, advances in the platform have significantly increased editing …
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
… Therapeutics is a NASDAQ-listed biotechnology company headquartered in Leiden, the Netherlands with an office in and Cambridge, Massachusetts, USA. In addition to our global presence, ProQR operates through a … machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase Acting on RNA), a protein which is …
… Therapeutics is a NASDAQ-listed biotechnology company headquartered in Leiden, the Netherlands with an office in … machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase Acting on RNA), a protein which is … we are looking for a senior Principal Scientist Liver to lead our liver portfolio Location: Leiden, NL (on-site) The …
